Among these, Gut Microbiome Modulates Response to Anti–PD-1 Immunotherapy in Melanoma Patients (burst strength: 4.67), Commensal Bifidobacterium Promotes Antitumor Immunity and Facilitates Anti–PD-L1 Efficacy (burst strength: 4.63), and Anticancer Immunotherapy by CTLA-4 Blockade Relies on the Gut Microbiota (burst strength: 4.63) ranked in the top three. This evidence concerns the gene CTLA4 and melanoma.